Salicylic Acid Modulation of MRSA Resistance and Virulence

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Methicillin-resistant Staphylococcus aureus (MRSA) infections are increasingly resistant to conventional antimicrobial therapies, leading to high mortality rates and significant healthcare costs, with limited pharmacologic approaches to mitigate resistance or enhance antibiotic efficacy.

Innovation Solution

Systemic administration of salicylic acid (SAL) or its analogues, such as diflunisal, in combination with antimicrobial agents like vancomycin, to modulate gene expression and virulence factors in MRSA, thereby enhancing antibiotic efficacy and reducing resistance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antimicrobial agents are used to treat MRSA infections, then treatment is provided for the infection, but bacterial resistance to these agents increases and therapeutic efficacy decreases

Engineering Contradiction:

Improveantibiotic efficacyVSAvoidbacterial resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the treatment approach by combining a conventional antimicrobial agent with a salicylic acid compound that acts through a different mechanism. The salicylic acid component targets bacterial resistance mechanisms separately from the primary antimicrobial action, dividing the problem of resistance into addressable parts.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The salicylic acid compound serves as an intermediary that modifies bacterial susceptibility to the primary antimicrobial agent. It mediates between the bacterial resistance mechanisms and the antimicrobial therapy, enhancing the effectiveness of the conventional agent without requiring development of entirely new antibiotics.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If new anti-staphylococcal antibiotics are developed, then resistance mitigation may be achieved, but development time and cost increase significantly

Engineering Contradiction:

Improveresistance mitigationVSAvoiddevelopment time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The invention applies preliminary action by using salicylic acid to pre-condition bacterial cells before exposure to the primary antimicrobial agent. This preliminary modification of bacterial susceptibility occurs through gene expression modulation, making the bacteria more vulnerable to the main treatment and achieving resistance mitigation without lengthy development cycles.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention changes biochemical parameters within bacterial cells through salicylic acid administration. It modifies gene expression profiles and bacterial physiological states, altering parameters such as virulence factor production and antibiotic susceptibility, thereby achieving enhanced treatment efficacy through parameter modification rather than structural redesign of antibiotics.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If higher doses of antimicrobial agents are administered to overcome resistance, then bacterial killing may be enhanced, but toxicity to the patient increases

Engineering Contradiction:

Improvebacterial killing efficacyVSAvoidpatient toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The salicylic acid compound changes bacterial physiological parameters and gene expression profiles, making bacteria more susceptible to lower concentrations of the primary antimicrobial agent. This parameter modification allows effective bacterial killing at reduced drug doses, thereby decreasing patient toxicity while maintaining or improving productivity.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9205097B2Anti-infective hydroxy-phenyl-benzoates and methods of use

Publication Date: 2015.12.08 LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT

AI summary

The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analog. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically co-administering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analog and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid.